SGMT Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -- compared to Sagimet Biosciences, Inc.'s net margin of --. Sagimet Biosciences, Inc.'s return on equity of -40.34% beat CEL-SCI Corp.'s return on equity of -230.36%.

Sagimet Biosciences, Inc. has a consensus price target of $28.14, signalling upside risk potential of 376.19%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 718.88%. Given that CEL-SCI Corp. has higher upside potential than Sagimet Biosciences, Inc., analysts believe CEL-SCI Corp. is more attractive than Sagimet Biosciences, Inc..

Sagimet Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Sagimet Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sagimet Biosciences, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Sagimet Biosciences, Inc. quarterly revenues are --, which are smaller than CEL-SCI Corp. quarterly revenues of --. Sagimet Biosciences, Inc.'s net income of -$12.9M is lower than CEL-SCI Corp.'s net income of -$6.1M. Notably, Sagimet Biosciences, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sagimet Biosciences, Inc. is -- versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

HCA Healthcare, Inc. has a net margin of -- compared to Sagimet Biosciences, Inc.'s net margin of 9.93%. Sagimet Biosciences, Inc.'s return on equity of -40.34% beat HCA Healthcare, Inc.'s return on equity of 3428.29%.

Sagimet Biosciences, Inc. has a consensus price target of $28.14, signalling upside risk potential of 376.19%. On the other hand HCA Healthcare, Inc. has an analysts' consensus of $481.95 which suggests that it could grow by 1.67%. Given that Sagimet Biosciences, Inc. has higher upside potential than HCA Healthcare, Inc., analysts believe Sagimet Biosciences, Inc. is more attractive than HCA Healthcare, Inc..

Sagimet Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison HCA Healthcare, Inc. has a beta of 1.361, suggesting its more volatile than the S&P 500 by 36.09%.

Sagimet Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. HCA Healthcare, Inc. offers a yield of 0.61% to investors and pays a quarterly dividend of $0.72 per share. Sagimet Biosciences, Inc. pays -- of its earnings as a dividend. HCA Healthcare, Inc. pays out 12% of its earnings as a dividend. HCA Healthcare, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sagimet Biosciences, Inc. quarterly revenues are --, which are smaller than HCA Healthcare, Inc. quarterly revenues of $19.2B. Sagimet Biosciences, Inc.'s net income of -$12.9M is lower than HCA Healthcare, Inc.'s net income of $1.9B. Notably, Sagimet Biosciences, Inc.'s price-to-earnings ratio is -- while HCA Healthcare, Inc.'s PE ratio is 18.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sagimet Biosciences, Inc. is -- versus 1.57x for HCA Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly & Co. has a net margin of -- compared to Sagimet Biosciences, Inc.'s net margin of 31.72%. Sagimet Biosciences, Inc.'s return on equity of -40.34% beat Eli Lilly & Co.'s return on equity of 106.26%.

Sagimet Biosciences, Inc. has a consensus price target of $28.14, signalling upside risk potential of 376.19%. On the other hand Eli Lilly & Co. has an analysts' consensus of $1,093.22 which suggests that it could grow by 1.34%. Given that Sagimet Biosciences, Inc. has higher upside potential than Eli Lilly & Co., analysts believe Sagimet Biosciences, Inc. is more attractive than Eli Lilly & Co..

Sagimet Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Eli Lilly & Co. has a beta of 0.370, suggesting its less volatile than the S&P 500 by 62.965%.

Sagimet Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly & Co. offers a yield of 0.56% to investors and pays a quarterly dividend of $1.50 per share. Sagimet Biosciences, Inc. pays -- of its earnings as a dividend. Eli Lilly & Co. pays out 44.39% of its earnings as a dividend. Eli Lilly & Co.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Sagimet Biosciences, Inc. quarterly revenues are --, which are smaller than Eli Lilly & Co. quarterly revenues of $17.6B. Sagimet Biosciences, Inc.'s net income of -$12.9M is lower than Eli Lilly & Co.'s net income of $5.6B. Notably, Sagimet Biosciences, Inc.'s price-to-earnings ratio is -- while Eli Lilly & Co.'s PE ratio is 53.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sagimet Biosciences, Inc. is -- versus 16.55x for Eli Lilly & Co.. Usually stocks with elevated PS ratios are considered overvalued.

Madrigal Pharmaceuticals, Inc. has a net margin of -- compared to Sagimet Biosciences, Inc.'s net margin of -39.75%. Sagimet Biosciences, Inc.'s return on equity of -40.34% beat Madrigal Pharmaceuticals, Inc.'s return on equity of -40.56%.

Sagimet Biosciences, Inc. has a consensus price target of $28.14, signalling upside risk potential of 376.19%. On the other hand Madrigal Pharmaceuticals, Inc. has an analysts' consensus of $603.47 which suggests that it could grow by 2.37%. Given that Sagimet Biosciences, Inc. has higher upside potential than Madrigal Pharmaceuticals, Inc., analysts believe Sagimet Biosciences, Inc. is more attractive than Madrigal Pharmaceuticals, Inc..

Sagimet Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals, Inc. has a beta of -1.034, suggesting its less volatile than the S&P 500 by 203.399%.

Sagimet Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Sagimet Biosciences, Inc. pays -- of its earnings as a dividend. Madrigal Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Sagimet Biosciences, Inc. quarterly revenues are --, which are smaller than Madrigal Pharmaceuticals, Inc. quarterly revenues of $287.3M. Sagimet Biosciences, Inc.'s net income of -$12.9M is higher than Madrigal Pharmaceuticals, Inc.'s net income of -$114.2M. Notably, Sagimet Biosciences, Inc.'s price-to-earnings ratio is -- while Madrigal Pharmaceuticals, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Sagimet Biosciences, Inc. is -- versus 17.65x for Madrigal Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.